Browsing by Author Paydas, S
Showing results 1 to 4 of 4
| Issue Date | Title | Author(s) |
|---|---|---|
| 2020 | Does primary tumor localization has prognostic importance in seminoma patients?: Turkish oncology Group study | Yildiz, B; Kucukarda, A; Gokyer, A; Demiray, Atike Gökçen ; Paydas, S; Aral, IP; Gumusay, O |
| 2019 | Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey | Beksac, M; Seval, GC; Paydas, S; Tuglular, TF; Arslan, O; Goker, H; Kaynar, L |
| 2011 | Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group. | Icli, F; Altundag, K; Coskun, U; Paydas, S; Basaran, G; Saip, P; Dogu, GG |
| 2017 | Nivolumab for relapsed or refractory hodgkin lymphoma: Experience in Turkey | Turgut, M. ; Hacioglu, S. Kabukcu ; Karadurmus, N; Paydas, S; Gulbas, Z; Turker, A; Toptas, T; Tuglular, T. Firatli; Tekgunduz, E.; Kaya, A. H.; Tastemir, N; Arat, M.; Tanrikulu, F. Pepedil; Ozkocaman, V.; Abali, H.; Ferhanoglu, B; Kaynar, L.; Karadogan, I.; Ozbalak, M.; Ozcan, M.; Dogu, M. H.; Bekoz, H; Yildirim, R.; Barista, I.; Demirkaya, M.; Koseoglu, F. D.; Yuksel, M. Kurt; Sonmez, M.; Toprak, S. K. |